The United States will distribute 60 million doses of the AstraZeneca COVID-19 vaccine to other countries over the next several months; workplace safety rules on COVID-19 submitted by Labor Department for review; White House reportedly will not include measures targeting drug prices in antipoverty package.
As reported by NPR, the White House announced yesterday during a press briefing that the United States will distribute 60 million doses of the AstraZeneca (AZ) COVID-19 vaccine to other countries over the next several months. Yet to be authorized in the United States while awaiting safety reviews by the FDA, the US government has previously sent excess AZ vaccines from its stockpile to Canada and Mexico. The White House did not specify which countries would receive the added shipments of the AZ vaccine, which has been shown to be 76% effective at preventing symptomatic COVID-19.
After setting a March 15 deadline to the Labor Department to decide whether mandatory workplace safety rules to protect workers against COVID-19 were warranted, the department sent the safety standards to the Office of Management and Budget (OMB) for review yesterday after weeks of delay and growing pressure from Democrats and safety advocates. POLITICO reports that the OMB’s Office of Information and Regulatory Affairs is expected to take 2 weeks before it publishes the requirements, which are expected to require employers to supply their workers with masks, have a written plan to prevent exposure, and take other precautions.
The White House is not planning to include any prescription drug pricing proposals sought by Democrats in Biden’s legislative package to address poverty, according to The Wall Street Journal. The paper reported that the antipoverty package will include funds for supporting the Affordable Care Act.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
2 Commerce Drive
Cranbury, NJ 08512